2009
Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer
2008
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection